Updates are available Correction dated 2026-04-24

Article History

Received: 1 August 2025

Accepted: 9 January 2026

First Online: 16 March 2026

Change Date: 24 April 2026

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1245/s10434-026-19737-4

Disclosure

: Roland L. Bassett was supported in part by an NIH/NCI Cancer Center Support grant (P30 CA016672). Sapna P. Patel reports institutional funding from 7 Hills, Immatics, Ionctura, Iovance, Linnaeus, and Replimune; consulting support from Daiichi Sankyo, IO Biotech, MSD, Natera, Novartis, Obsidian, Pfizer, Replimune, Scancell, TriSalus Life Sciences, and Veda trials. Ashley M. Holder had grant support from the American College of Surgeons Clowes Award and the Department of Defense CDMRP Melanoma Academy Scholar Program. Rodabe N. Amaria had trial support from Obsidian, KSQ, Regeneron, Immatics, Erasca, and OnKure. Michael A. Davies: was supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH/NCI P50CA221703, the American Cancer Society, and the Melanoma Research Alliance, Cancer Fighters of Houston, the Anne and John Mendelsohn Chair for Cancer Research, and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson. He also has been a consultant to Replimmune, Nurix, Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, Merck, and ABM Therapeutics, as well as a scientific advisory board member for THERAtRAME. In addition, he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, Pfizer, ABM Therapeutics, and LEAD Pharma. Merrick I. Ross serves as a melanoma advisory board consultant for Merck Inc and has received travel expenses related to this role. Roi Weiser has received grant support by the SWOG/Hope Foundation Impact Award. Hussein A. Tawbi reports consulting or advisory roles for Bristol Myers Squibb, Merck, Novartis, Medicenna, Iovance, Eisai, Pfizer, Roche, IO Biotech, Krystal Biotech, Immunocore, Regeneron, Corcept Therapeutics, Strand Therapeutics, and T-Kinfe Therapeutics, as well as research funding from Bristol Myers Squibb, Novartis, Dragonfly Therapeutics, GlaxoSmithKline, Merck, and Roche, Regeneron, Dragonfly Therapeutics, Syntrix Adi K. Diab serves as an advisory board member for-Memgen INC and as a consultant for Regeneron. The remaining authors have no conflicts of interest.